Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2025PharmaceuticalsOpen Access

New-Onset Diabetes After Transplantation in Renal Recipients: A Pilot Comparative Study of Immediate vs. Extended-Release Tacrolimus Formulation

View Full Paper
Ask AI
Bookmark
Share

Authors

IRIoana Adela RaţiuFBFlorin BănicăCMCorina Moisa

Discussion

Loading...

Member takes

Overview

Pilot study compares incidence of new-onset diabetes after transplantation between tacrolimus formulations, suggesting no significant differences.

Key Points

  • The study found no significant differences in new-onset diabetes after transplantation between tacrolimus formulations.
  • NODAT incidence was 42.4% for extended-release tacrolimus and 39.4% for immediate-release, with a p-value of 0.802.
  • This retrospective pilot study included 66 renal transplant patients followed for 5 years to assess diabetes incidence.
  • These findings highlight the need for larger studies to validate the relationship between tacrolimus release characteristics and clinical outcomes.

Cite This Study

Raţiu et al. (2025) studied this question.

synapsesocial.com/papers/68efa18f9d05deea71d13d3bhttps://doi.org/10.3390/ph18101532
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study2010 · 169 citations
  2. 2Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial2020 · 12 citations
  3. 3Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study2021 · 19 citations
  4. 4Dyslipidemia in Renal Transplant Recipients2022 · 22 citations